Navigation Links
Mylan Launches Thiamine Hydrochloride Injection
Date:6/28/2012

PITTSBURGH, June 28, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Institutional business has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for preservative-free Thiamine Hydrochloride Injection, 100 mg/mL, packaged in 200 mg/2 mL multiple-dose vials. This product is indicated for the treatment of thiamine deficiency.

Thiamine Hydrochloride Injection, 100 mg/mL, had U.S. sales of approximately $18.6 million for the 12 months ending March 31, 2012, according to IMS Health. Mylan is shipping this product, presented in 25-vial packs, immediately.

Currently, Mylan has 169 ANDAs pending FDA approval representing $83.9 billion in annual sales, according to IMS Health. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $25.6 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around th
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
(Date:8/1/2014)... (PRWEB) August 01, 2014 Millions of ... affects the legs and in some cases the arms, ... state that about 17 million women in the U.S. ... women dealing with the pain, embarrassment and discomfort caused ... even some physicians are unaware that this is a disease,” ...
(Date:8/1/2014)... August 01, 2014 Get the report ... with PitchBook presents the 3Q 2014 Private Equity Breakdown ... equity investment, exits and fundraising activity in the second ... help plan for private equity endeavors for the remainder ... to download it now. , About Merrill DataSite , ...
(Date:7/31/2014)... The 2013 edition of the ... listings, appellate decisions, litigation and settlement trends, trials, ... with California's Proposition 65. , The Handbook is ... history and trends impacting California's Proposition 65. ... the series which adds approximately 200 pages devoted ...
(Date:7/31/2014)... Women who recently used birth control pills containing ... increased risk for breast cancer, whereas women using some ... Cancer Research , a journal of the American ... use of contemporary oral contraceptives [birth control pills] in ... cancer risk relative to never or former oral contraceptive ...
(Date:7/31/2014)... July 31, 2014 Leelanau Peninsula’s newest winery, ... 3, 2014 at 7788 East Horn Road in Lake Leelanau. ... Trail , Aurora Cellars is the 25th winery along the ... the popular wine tour events, making its trail event debut ... 2014. , Owners David and Faye Mathia opened the ...
Breaking Medicine News(10 mins):Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... ... Model 362 portable spa to the Eagle Condor Humanitarian foundation to benefit several impoverished villages ... (Vocus) ... a Model 362 portable hot tub for auction at a fundraising event for ...
... ... pleased to announce that Aaron Alsop has achieved the Project Management Professional (PMP) ... ... DTM Systems Corporation is pleased to announce that Aaron Alsop has achieved the ...
... ... Creation Processes , ... Naples, FL (PRWEB) July 8, 2010 -- QualEDIx, a leading provider of HIPAA ... AgilEDIx, a real-time HIPAA 5010 and ICD-10 test data generation and management service. ...
... (CF) recover from exacerbations equally well if they are ... researchers from Johns Hopkins University. Furthermore, longer treatment with ... over shorter courses. The study was published ... Thoracic Society,s American Journal of Respiratory and Critical ...
... Study suggests that physical activity has little if any role ... the key factor behind diabetes, heart disease and some cancers. ... Plymouth, UK, and has been observing in detail a cohort ... A review published in 2009 of all trials using physical ...
... HealthDay Reporter , WEDNESDAY, July 7 (HealthDay News) ... United States is likely to last through the weekend, taxing ... and air conditioning and fans up and running. And ... only making matters worse, meteorologists say. On Tuesday, ...
Cached Medicine News:Health News:Another Reason to Buy a Hot Tub: Bullfrog Donates Spa to Humanitarian Effort 2Health News:Another Reason to Buy a Hot Tub: Bullfrog Donates Spa to Humanitarian Effort 3Health News:DTM Systems Is Pleased To Announce That Aaron Alsop Has Achieved The Project Management Professional Credential With The Project Management Institute 2Health News:QualEDIx Announces the Launch of the Nation's Only Managed Service Model for HIPAA 5010 and ICD-10 Testing 2Health News:Home care equivalent to hospital care for some patients with cystic fibrosis 2Health News:Home care equivalent to hospital care for some patients with cystic fibrosis 3Health News:Inactivity 'no contributor' to childhood obesity epidemic 2Health News:Relentless Heat Threatens Your Health 2Health News:Relentless Heat Threatens Your Health 3Health News:Relentless Heat Threatens Your Health 4
... Focus Diagnostics HerpeSelect® 1 ELISA IgG ... or absence of human IgG class antibodies ... the Focus HerpeSelect® 2 ELISA IgG, the ... or expectant mothers for aiding in the ...
Perfect for loading small volume samples onto agarose and polyacrylamide gels....
Conducting disposable filter-tips....
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
Medicine Products: